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Abstract
Background: Human globin gene expression is precisely regulated by a complicated network of transcription factors and
chromatin modifying activities during development and erythropoiesis. Eos (Ikaros family zinc finger 4, IKZF4), a member of
the zinc finger transcription factor Ikaros family, plays a pivotal role as a repressor of gene expression. The aim of this study
was to examine the role of Eos in globin gene regulation.
Methodology/Principal Findings: Western blot and quantitative real-time PCR detected a gradual decrease in Eos
expression during erythroid differentiation of hemin-induced K562 cells and Epo-induced CD34+ hematopoietic stem/
progenitor cells (HPCs). DNA transfection and lentivirus-mediated gene transfer demonstrated that the enforced expression
of Eos significantly represses the expression of c-globin, but not other globin genes, in K562 cells and CD34+ HPCs.
Consistent with a direct role of Eos in globin gene regulation, chromatin immunoprecipitaion and dual-luciferase reporter
assays identified three discrete sites located in the DNase I hypersensitivity site 3 (HS3) of the b-globin locus control region
(LCR), the promoter regions of the Gc- and Ac- globin genes, as functional binding sites of Eos protein. A chromosome
conformation capture (3C) assay indicated that Eos may repress the interaction between the LCR and the c-globin gene
promoter. In addition, erythroid differentiation was inhibited by enforced expression of Eos in K562 cells and CD34+ HPCs.
Conclusions/Significance: Our results demonstrate that Eos plays an important role in the transcriptional regulation of the
c-globin gene during erythroid differentiation.
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Introduction
The human b-globin locus consists of five functional globin genes
(e,G c,A c, d,a n db) within a 70 kb domain. During development
expression of these genes displays two switches, the embryonic (e-) to
fetal (Gc-a n dA c-) globin switching, coinciding with the transition
from yolk sac to fetal liver, and the fetal to adult (b-) globin switching,
occurring near the parturient period with the establishment of bone
marrow as the main site of hematopoiesis [1,2]. During erythroid
differentiation the c-t ob-gloin gene switching is also displayed and it
is called ‘‘compressed switching’’ [3]. The precise developmental
program of human b- l i k eg l o b i ng e n ee x p r e s s i o ni sg o v e r n e db ya
diverse array of regulatory mechanisms. Sequences within or
immediately flanking globin genes control expression in tissue-specific
or temporal patterns. High-level globin expression is directed by the
locus control region (LCR), a set of key regulatory sequences 6–20 kb
upstream of the e-globin gene, that are characterized by the presence
of five 59 DNase I hypersensitivity sites (HSs) [4]. Preferential
interactions between the LCR and individual globin promoters
during distinct developmental stages are pivotal to the strict
regulation of globin gene expression. These interactions are mediated
by erythroid tissue-restricted and ubiquitous transcription factors.
Because fetal c-globin gene reactivation in adults has potential
as an effective therapy for sickle cell anemia and b-thalassemia
[5], the detailed characterization of c-globin gene regulation
mechanisms is particularly significant. Several studies have
reported transcriptional activation of the c-globin gene by FKLF
[6], FKLF2 [7], NF-E4 [8] and NF-Y [9]. However, repressors
also play a critical role during c-t ob-globin switching. The
repressors BCL11A [10], Ikaros [11], GATA-1 [12], the orphan
nuclear receptors TR2 and TR4 [13], and NF-E3/COUP-TFII
[14] have been associated with human c-globin gene silencing.
Despite avid research regarding c-globin gene regulation, the
mechanisms responsible for c-globin gene silencing are not fully
understood.
Eos, also known as IKZF4, is a member of the zinc finger
transcription factor Ikaros family characterized by the presence of
four DNA-binding N-terminal zinc fingers and two C-terminal
zinc fingers required for homo- and heterodimerization with other
Ikaros family members [15]. Ikaros family of genes consists of
several members: Ikaros (IKZF1), Aiolos (IKZF3), Helios (IKZF2),
Eos (IKZF4) and Pegasus (IKZF5). The Ikaros family of
transcription factors acts as key repressors of transcription during
the development and function of lymphocytes [16–19]. Ikaros is
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binding to critical cis elements implicated in the gene switching
and facilitating long-distance DNA looping between the LCR and
a region upstream of d-globin. When the DNA-binding region of
Ikaros is disrupted by a point mutation in plastic mice,
concomitant marked downregulation of b-globin expression and
upregulation of c-globin expression are observed [20]. Eos is a 585
amino acid highly conserved zinc finger transcription factor that
binds typical WGGGAAT Ikaros recognition sites in DNA and
functions as a transcriptional repressor (Figure S1) [21]. Eos may
also play an important role in the development of the central and
peripheral nervous systems [22,23]. Eos can self-associate, form
heterodimers with other Ikaros family members, or interact with
C-terminal binding protein (CtBP2), PU.1, or microphthalmia-
associated transcription factor (MITF) to repress transcription of
cathepsin K and tartrate-resistant acid phosphatase (TRAP)
promoters [21,24]. Eos is expressed at low levels in kidney,
thymus, liver and heart and at high levels in skeletal muscle [23].
Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory
T cells by interacting directly with Foxp3 and inducing chromatin
modifications that result in gene silencing in CD4+ regulatory T
cells [19]. Although it has known that Eos protein is expressed in
lymphocytes and is implicated in the control of lymphoid cell
development, the function of Eos in the regulation of other
haemopoietic lineage has not been addressed.
In this study, we examined the effects of Eos on human globin
gene regulation and demonstrated its important role in c-globin
gene regulation during erythroid differentiation.
Results
Eos represses c-globin gene expression in K562 cells
during erythroid differentiation
Hemin-induced erythroid differentiation of K562 cells was
evaluated using the benzidine cytochemical test. Western blot and
quantitative real-time PCR indicated that the protein (Figure 1A)
and mRNA (Figure 1B) expression of Eos gradually decreased
during hemin-induced erythroid differentiation. Conversely, a
substantial increase in c-globin expression was observed during
erythroid differentiation of K562 cells (Figure 1A and 1C). The
reciprocal association of Eos and c-globin gene expression
following hemin induction in K562 cells supports the hypothesis
that the Eos protein might repress c-globin expression. To study
the effect of Eos on c-globin gene expression, K562 cells were
transfected with an Eos expression plasmid (pcDNA3.1-Eos), and
overexpression of Eos was confirmed by Western blotting
(Figure 1D). Northern blotting revealed that overexpression of
Eos significantly downregulated transcription of the c-globin gene
but had little effect on transcription of the a- and e-globin genes in
K562 cells before and after erythroid differentiation (Figure 1E).
Quantitative real-time PCR results were consistent with Northern
blotting (Figure 1F and 1G). These results support a specific
repressive function of Eos on the human c-globin gene.
Eos represses c-globin gene expression in stable
m’LCRAcybdb/GM979 transformants
Because the b-globin gene is not expressed in K562 cells, the
effect of Eos on human b-globin cannot be examined in K562
cells. Thus, we used stable MEL GM979 transformants with
integration of human b-globin gene cluster. GM979, a MEL cell
line which expresses both murine embryonic and adult globins, is
an appropriate model system to study human globin gene
expression [25]. The human Eos protein is not detected by
human Eos antibody in GM979 (Figure S2). A linearized cosmid
construct m’LCRAcybdb (Figure 2A), which contained a 3.1 kb
m’LCR cassette, a subset consisting of the impact core sequences of
four of the DNaseI hypersensitive sites, linked to a 29 kb fragment
from the human Ac-t ob-globin genes with the natural
chromosome arrangement, has been demonstrated a correct
developmental expression of human globin genes in transgenic
mice [12]. GM979 cells were cotransfected with the linearized
cosmid construct m’LCRAcybdb and the pTKneo plasmid by
electroporation. Stable transformant cells were elected in medium
containing G418. Stable m’LCRAcybdb/GM979 transformants
were subsequently transfected with pcDNA3.1-Eos or control
vector (pcDNA3.1) respectively. Eos expression then was analyzed
by Western blot (Figure 2B). The levels of human Ac- and b-
globin transcripts as well as endogenous murine a-globin
transcripts were measured by Northern blot (Figure 2C) and
quantitative real-time PCR (Figure 2D). A significant decrease in
transcription of human c-globin was observed in m’LCRAcybdb/
GM979 cells overexpressing Eos, whereas human b-globin and
murine a-globin transcripts were not significantly affected. These
results further supported a specific repressive function of Eos on
the expression of human c-globin gene.
Identification and validation of functional Eos binding
sites within the human b-globin gene cluster
To investigate whether Eos represses c-globin expression by
direct association with the human b-globin locus, we searched the
human b-globin locus for matches to the Eos binding motif
(WGGGAAT). Thirty-two putative Eos binding sites were
identified in the b-globin locus (Figure 3A). Chromatin immuno-
precipitation (ChIP) was performed using an anti-Eos antibody.
Using DNA fragments precipitated with anti-Eos as templates,
twenty-eight pairs of primers were designed to amplify the regions
containing each of the putative Eos binding sites (Table S1). Of
these Thirty-two putative Eos binding sites in the human b-globin
cluster, only three discrete regions, which located in the HS3 of
LCR, the promoter regions of Gc- and Ac-globin genes, were
confirmed to be occupied by Eos protein (Figure 3B). A significant
reduction of Eos combination at these three binding sites was
observed in K562 cells following 48 h of hemin induction,
compared with uninduced cells, when the immunoprecipitated
DNA was quantified by real-time PCR and compared with the
relevant input DNA (Figure 3C). This is consistent with the
observed decrease in Eos protein and mRNA expression following
hemin induction of K562 cells (Figure 1A and Figure 1B).
To investigate the effect of Eos on the expression of c-globin
gene, a series of dual-luciferase reporter assays were performed in
K562 cells. Firstly, a recombinant plasmid including the 1.4-kb c-
globin promoter (pGL3-basic 21383/+49 Gc/Luc) was con-
structed and was cotransfected with various concentrations of the
Eos expression vector (pcDNA3.1-Eos). Dual-luciferase reporter
assays indicated that Eos repressed c-globin promoter activity in a
dose-dependent manner (Figure 4A). When 1 mg of the
pcDNA3.1-Eos plasmid was used in luciferase reporter assays,
the luciferase activity of pGL3-basic 21383/+49 Gc/Luc was
reduced to about 50% of the activity observed in the absence of
the pcDNA3.1-Eos vector. To validate precise sites of silencing
elements bound by Eos in the c-globin promoter, a series of
truncated c-globin promoters (21383/+49, 2998/+49, 2864/
+49, and 2562/+49) linked to a luciferase reporter gene
respectively were cotransfected with pcDNA3.1-Eos or pcDNA3.1
empty vector respectively. Deletion analyses revealed that the
region between 2998 and 2864 of the promoter was responsible
for the negative effect of Eos overexpression on c-globin promoter
activity (Figure 4B). Mutants containing 21383 to +49 or 2998 to
Regulation of Human c-globin Gene by Eos
PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e22907Figure 1. Eos represses c-globin gene expression specifically in K562 cells. (A) Western blot analysis indicated a decrease in Eos protein
levels and a marked increase in c-globin levels during erythroid differentiation of hemin-induced K562 cells. (B–C) Quantitative real-time PCR analysis
of Eos and c-globin mRNA expression in K562 cells following hemin treatment for 0, 12, 24, or 48 h. (D) Western blot analysis of Eos protein levels in
untransfected, pcDNA3.1-transfected, and pcDNA3.1-Eos-transfected K562 cells. (E) Northern blot analysis of c-, e-, and b-globin gene expression in
K562 cells before and after 48 h treatment with hemin. K, C, and E represent K562 cells, K562 cells transfected with pcDNA3.1, and K562 cells
transfected with pcDNA3.1-Eos, respectively. (F) Relative globin mRNA levels in untransfected, pcDNA3.1- and pcDNA3.1-Eos-transfected K562 cells
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binding motif (at approximately position 2930) were analyzed by
luciferase reporter assay in K562 cells, with cotransfected
pDNA3.1-Eos or pDNA3.1. When the Eos binding motif was
mutated, overexpression of Eos was not repressive to c-globin gene
expression compared with control (Figure 4C). We generated a
pGL3-basic m’LCR-c-globin promoter luciferase reporter con-
struct by fusing the 1.4-kb m’LCR linked to the c-globin promoter
with the luciferase reporter gene in the pGL3-basic vector
(Figure 4D). We also generated a series of mutants, including
single mutations in the Eos binding site of the LCR or c-globin
promoter and dual-mutations in two of the Eos binding sites. The
relative luciferase activity in the K562 cells transfected with the
reporter construct containing the m’LCR was 6.5 times greater
than that in the K562 cells transfected with the reporter construct
without m’LCR, and cotransfection with pDNA3.1-Eos reduced
luciferase activity significantly. The single mutation of the Eos
binding site in LCR partially restored luciferase activity of the
LCR-c-globin promoter construct. The single mutation of the Eos
binding site in the c-globin promoter significantly rescued of
luciferase activity. Mutations in both of these sites resulted in a
near complete restoration of the luciferase activity. These results
suggest that these sites were functional Eos binding sites required
for repressive effect of Eos on c-globin gene.
The interaction between LCR and the c-globin promoter
is inhibited by Eos
To ascertain the mechanisms by which Eos inhibits c-globin
gene transcription we performed a chromosome conformation
capture (3C) assay in the presence or absence of enforced Eos
expression to test if Eos affects the interaction between LCR and
the c-globin promoter in K562 cells. Restriction enzyme XbaI was
used and an XbaI-digested DNA fragment that includes LCR
HS2/3/4 was elected as fixed region, herein referred to as
fragment 1. The relative cross-linking efficiency between fragment
1 and other XbaI fragments then was measured by quantitative
real-time PCR. Fragment 1 exhibited significantly higher relative
cross-linking efficiencies with fragments 6 that includes Gc-globin
promoter and 7 that includes Ac-globin promoter than with the
other fragments (Figure 5), consistent with the predominant
were analyzed by quantitative real-time PCR. The relative level of each globin mRNA is shown as the fold value of the mRNA level in untreated K562
cells. (G) Relative globin mRNA levels before or after hemin-inducted K562 cells were analyzed by quantitative real-time PCR. The relative level of each
globin mRNA is shown as fold value of the level of e-globin mRNA in untreated K562 cells. Each experiment was performed in triplicate, and mRNA
levels were normalized to GAPDH or b-actin mRNA expression. Error bars represent one standard deviation. *P,0.05, #P,0.01.
doi:10.1371/journal.pone.0022907.g001
Figure 2. Overexpression of Eos reduces c-globin gene expression in m’LCRAcybdb/GM979 cells. (A) Structural diagram of the integrated
construct m’LCRAcybdb, in which a 3.1-kb m’LCR cassette is linked to a 29-kb fragment from the human Ac-t ob-globin gene. (B) Eos protein level was
analyzed by Western blot in m’LCRAcybdb/GM979 cells that were untreated and transfected with pcDNA3.1 or pcDNA-Eos. (C) The expression levels
of human c-, b-, and murine a-globin genes were analyzed by Northern blot in stable m’LCRAcybdb/GM979 transformants. Each globin mRNA level
was normalized to murine b-actin mRNA. M, C, and E represent m’LCRAcybdb/GM979 cells that were untransfected, transfected with pcDNA3.1
(control), and transfected with pcDNA3.1-Eos, respectively. (D) Human c-, b-, and murine a-globin mRNA levels were measured by quantitative real-
time PCR. Each PCR analysis was performed in triplicate, and expression levels were normalized to murine b-actin mRNA. Error bars represent
standard deviation. *P,0.05.
doi:10.1371/journal.pone.0022907.g002
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genes in K562 cells. In the presence of enforced Eos, a significant
decrease in the interaction between the LCR and the c-globin
promoter was detected both before and after hemin induction
(Figure 5). The repressive effect of Eos on c-globin transcription
may be partialy attributed to the inhibition of Eos on the
formation of a physical and functional link between the LCR and
the c-globin promoter.
Eos overexpression reduces c-globin gene expression in
CD34+ HPCs derived from umbilical cord blood
Human CD34+ HPCs were isolated from human umbilical cord
blood (UCB) and were induced to erythroid differentiation using
Epo.TheEosmRNAleveldecreasedgraduallyduringEpo-induced
erythroid differentiation of CD34+ HPCs, as measured by
quantitative real-time PCR (Figure 6A). CD34+ HPCs were
infected with the lentivirus control (Lenti-control) and the lentivirus
withEosoverexpression(Lenti-Eos)respectively.Thehigh lentivirus
transduction efficiency of the CD34+ HPCs was observed through
GFPexpression (datanot shown), and overexpressionofEosmRNA
in CD34+ HPCs infected with lenti-Eos was confirmed by
conventional RT-PCR (Figure 6B) and quantitative real-time
PCR (Figure 6C). Globin mRNA levels in lentivirus-infected
CD34+ HPCs at 3, 7, 11, and 15 day of erythroid differentiation
also were analyzed by quantitative real-time PCR (Figure 6D).
Compared to untransfected and lenti-control-transfected CD34+
HPCs, a significant reduction of c-globin, but not b-globin, gene
expression was observed in CD34+ HPCs transfected with lenti-Eos
at each time point of erythroid differentiation (Figure 7A). This
suggested enforced Eos expression specifically and continuously
inhibited c-globin gene expression in vivo. Eos appeared to have a
minimal effect on c-globin gene expression prior to Epo induction.
This is probably because CD34+ HPCs are a mixture of cells
including HSCs and various progenitors, and c-globin mRNA has
minimal expression in CD34+ HPCs.
Additionally, after 7 d of erythroid induction culture when the
c-t ob-globin switching appears, a slight increase in b-globin gene
expression and an obvious decrease in c-globin gene expression
were detected in lenti-Eos-infected cells compared with controls.
Concomitantly, lenti-Eos-infected cells exhibited a slightly more
rapid reduction in the ratio of c to [c+b]-globin mRNA compared
with controls (Figure 7B).
Enforced expression of Eos inhibits erythroid
differentiation
To examine the role of Eos in erythroid differentiation,
untransfected K562 cells and K562 cells transfected with
pcDNA3.1 or pcDNA3.1-Eos were induced by hemin. Erythroid
Figure 3. Identification of Eos-binding sites in the b-globin cluster. (A) A schematic representation of the human b-globin gene locus.
Putative Eos-binding sites (containing WTGGGAA sequence) are shown as vertical lines. Positive ChIP-PCR amplification was obtained using P1–P2,
P7–P8, and P9–P10, with P3–P4 and P5–P6 as negative controls. Eos-binding sites and flanking sequences are depicted, and mutated nucleotides are
indicated as red in mutation assays. (B) ChIP-PCR assays of Eos binding in K562 cells. Amplified fragments using the indicated primers and antibodies
demonstrated binding of Eos to the promoter regions of the Gc- and Ac-globin genes and to the LCR region in K562 cells. K and HK represent
untreated K562 cells and K562 cells treated with hemin for 48 h, respectively. (C) Quantitative ChIP analysis of Eos binding to the b-globin gene locus
before and after hemin induction in K562 cells. Experimental PCR products were normalized to the PCR products of relevant input DNA. The ‘‘K+IgG’’
and ‘‘K+Eos Ab’’ designations represent the relative occupancies of IgG and Eos antibody, respectively, in the b-globin gene locus before induction.
The ‘‘HK+IgG’’ and ‘‘HK+Eos Ab’’ designations indicate the relevant expression after hemin induction. The bar graphs represent averages of three
independent ChIP experiments. Error bars depict standard deviation.
doi:10.1371/journal.pone.0022907.g003
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cytometric analysis of the erythroid markers transferrin receptor
(CD71) and anti–glycophorin A (CD235a). A marked decrease in
benzidine-positive cells was observed in K562 cells transfected with
pcDNA3.1-Eos compared with untransfected cells or cells trans-
fected with control vector (Figure 8A). Representative photos of
benzidine-stained K562 cells after 24 or 48 h of hemin induction
are showed in Figure 8B. In accordance with benzidine staining
results, lower expression levels of CD71 (Figure 8C) and CD235a
(Figure 8D) were observed in K562 cells transfected with
pcDNA3.1-Eos compared with cells transfected with control vector
when the cells were induced by hemin for 48 h.
CD235a also was examined by quantitative real-time PCR
and flow cytometric analysis during Epo-induced erythroid
differentiation of CD34+ HPCs. Cells infected with lenti-Eos
exhibited a reduction in CD235a at each time point during Epo
induction compared with controls (Figure 8E). The flow
cytometric analysis also demonstrated a decreased expression
in CD235a in the erythroid induction culture of CD34+ HPCs
infected with lenti-Eos compared with cells infected with
lenti-control at day 15 after Epo induction (Figure 8F). These
results suggest that overexpression of Eos inhibits erythroid
differentiation.
Discussion
In this study, we identified Eos as a repressor of the c-globin
gene during erythroid differentiation in K562 cells and in CD34+
Figure 4. Validation of functional Eos-binding sites in the b-globin cluster using luciferase reporter assays. (A) Eos represses c-globin
promoter activity in a dose-dependent manner. Luciferase reporter assays were performed in K562 cells. The recombinant pGL3-basic-1.4 kb c-globin
promoter (21383/+49) construct was cotransfected into K562 cells with increasing amounts of the pcDNA3.1-Eos expression vector. (B) Truncation
analysis of c-globin promoter activity in K562 cells. Cells were cotransfected with pGL3-basic-c-globin promoter constructs at various lengths and
either pcDNA3.1 (i.e., empty vector) or pcDNA3.1-Eos. Promoter/reporter gene constructs with different c-globin promoter lengths are depicted
along the left. (C) Mutation analysis of c-globin promoter activity in K562 cells. pGL3 constructs with different c-globin promoter regions (21383/+49
or 2998/+49) and with normal or mutated sequences were cotransfected with pcDNA3.1 (i.e., empty vector) or with pcDNA3.1-Eos into K562 cells.
(D) The luciferase reporter construct consists of the 3.1-kb m’LCR, the 1.4-kb c-globin promoter, and the luciferase reporter in the pGL3-basic plasmid
(see Materials and Methods). pGL3 constructs with normal or mutated sequences in the LCR or c-globin promoter were cotransfected with pcDNA3.1
or pcDNA3.1-Eos into K562 cells, and luciferase activities were determined. Luciferase reporter assay data are expressed as percentages of control (i.e.,
cells transfected with pcDNA3.1 alone) and represent the means 6 SE of three separate experiments after correcting for differences in transfection
efficiency by pRL-TK activities. Error bars represent one standard deviation. *P,0.05, #P,0.01.
doi:10.1371/journal.pone.0022907.g004
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could negatively regulate c-globin gene expression, whereas stem
cell factor (SCF) induces c-globin gene expression by decreasing
COUP-TFII expression [14]. Cohen-Barak et al. reported that
Sox 6 binds to the ey-globin gene promoter and represses gene
transcription in mice [26]. BCL11A, a multi-zinc finger transcrip-
tion factor, was originally linked to c-globin levels in humans by a
genome-wide association strategy [27]. The knockdown of
BCL11A with small interfering RNA resulted in an increase in c-
globin without affecting the expression of other erythroid-specific
proteins, such as GATA-1, FOG-1, NF-E2, or EKLF. BCL11A
was significantly recruited at HS3 of the LCR and at two sites
between the Ac- and d-globin genes that were previously
implicated in developmental silencing of the c-globin gene [10].
As a member of the Ikaros family, Ikaros protein is recruited to the
human b-globin locus and targets the histone deacetylase,
HDAC1, and the chromatin remodeling protein, Mi-2, to the
human c-gene promoters, and thereby contributing to c-globin
gene silencing at the time when the c-t ob-globin gene switching
happens [11].
Because a high level of Eos protein expression was detected in
K562 cells (Figure S2) and K562 cells have been widely used as a
model for the study of globin gene regulation and erythroid
differentiation, we examined the effects and mechanisms of Eos on
globin gene expression in K562 cells. Since K562 cells do not
endogenously express b-globin, we also stably transformed
m’LCRAcybdb/GM979 with the human b-globin gene cluster
and used erythroid induction cultures of CD34+ HPCs to examine
the effects of Eos on globin gene expression. A specific, negative
regulatory effect of Eos on the c-globin gene was demonstrated in
all of the three experimental systems.
ChIP-PCR indicated a reduction in Eos proteins bound to the
three positive Eos binding sites in the b-globin cluster in the
hemin-induced K562 cells compared with uninduced K562 cells
(Fig. 3B). This phenomenon could be relevant to the gradual
decrease in Eos protein during erythroid differentiation, and it is
consistent with the increase in c-globin gene expression owing to a
decrease in Eos repression following hemin induction. Promoter
truncation analyses suggested the present of a silencing element
between 2998 and 2864 of the c-globin promoter that could bind
Eos protein. Mutation (TCCC to GAAA) of the Eos binding motif
from 2929 to 2933 in a 1.4-kb of the c-globin promoter resulted
in the nearly complete restoration of luciferase activity in K562
cells expressing a reporter construct and overexpressing Eos. The
LCR’s influence on c-globin gene expression was displayed by
dual-luciferase reporter assay using a pGL3-basic m’LCR-c-globin
promoter luciferase reporter construct (Figure 4D). The enforced
expression of Eos significantly decreased the luciferase activity.
Either a mutation in the Eos binding site in the LCR, or a
mutation in the binding site in the c-globin promoter region
resulted in a partially restoration of the luciferase activity.
Mutations in both of the two sites resulted in a near complete
restoration of the luciferase activity. In the dual-luciferase reporter
assays, we speculated that Eos bound to the sites is involved in
formation of a repression complex with other protein and the
repression complex also reduces the interaction between the LCR
and the c-globin promoter.
We also detected expression of some transcription factors
(BCL11A, Ikaros, TR2, TR4, NF-E3, GATA1, EKLF and
FKLF), which had been reported to play important roles in c-
globin gene regulation, before and after hemin induction of K562
cells. Real-time PCR assay did not detect significantly change in
the expression of these transcription factors when Eos was
overexpressed in K562 cells (Figure S3). The results suggested
that the c-globin gene regulation by Eos is not a consequence of
the modification in expression of these transcription factors by Eos.
Our 3C assay revealed that HS4, HS3, and HS2 in LCR
function as a whole to interact with the c-globin promoter and
regulate gene expression. This is consistent with the previous
finding that individual HS core elements interact with the
transacting factors bound to the HSs to form a higher-order
structure referred to as the LCR ‘‘holocomplex’’ [28]. The
repressive effect of Eos on the interaction between the LCR and
the c-globin promoter in K562 cells after hemin induction is more
noticeable than before hemin induction (Figure 5). This might be
an indirect consequence of Eos influence on K562 cell
differentiation.
Our results demonstrated that enforced Eos expression reduced
the proportion of benzidine-positive cells compared with control
during erythroid differentiation of hemin-induced K562 cells. This
was accompanied by decreased expression of CD235a and CD71
(Figure 8), suggesting that Eos may inhibit erythroid differentiation
of K562 cells. The increased c-globin gene expression is an
indicator of erythroid differentiation of hemin-induced K562 cells
and Epo-induced CD34+ hematopoietic stem/progenitor cells. So
the dual effect of Eos on erythroid differentiation and the c-globin
Figure 5. Eos decreases the interaction between the LCR and
the c-globin region promoters. (A–B) The human b-globin locus
was analyzed by 3C assay in K562 cells that were (A) untransfected or
transfected with pcDNA3.1-Eos, or (B) that were untransfected or
transfected with pcDNA3.1-Eos and hemin-induced for 48 h. The
relative positions of b-like globin genes are represented as black
arrows along the top of each graph. The thick line (1) indicates the
position and size of the fixed fragment 1 (LCR HS2/3/4), and the thin
lines (2–11) show the position and size of other XbaI fragments. Data
are presented as mean 6 SEM (n=3) cross-linking frequencies between
the LCR (HS2/3/4) and differentiation fragments, Error bars represent
one standard deviation. *P,0.05.
doi:10.1371/journal.pone.0022907.g005
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enforced Eos expression did not significantly reduce transcription of
other globin genes during erythroid differentiation in either K562
cells or CD34+ HPCs, which demonstrated a specific negatively
regulation effect of Eos on the c-globin gene. These also suggested
that the increase of c-globin expression during erythroid differen-
tiation is not only a consequence of the effect of Eos on erythroid
differentiation. There may be different mechanisms for the
repression from Eos on erythroid differentiation and the c-globin
gene expression. In this study, we examined mainly the mechanisms
for which Eos regulates the c-globin gene transcription.
The mammalian b-globin gene locus is a very well-characterized
model system for studying long-range chromosomal interactions
during erythropoiesis. The LCR is the major structural component
of the human b-globin locus, and it is required for high-level globin
gene transcription[29].Thehumanb-globin LCRcontains binding
sites for several transcription factors, including NFE2, EKLF,
GATA-1, and Sp1 [30]. Other reports strongly suggested that
contacts between the LCR and various genes of the b-globin locus
are developmentally controlled and are required for the LCR to
influence the expression rates of individual globin genes [31,32].
The results of our 3C assay indicated that Eos regulates c-globin
gene expression by inhibiting the interaction between the LCR and
the c-globin promoter (Figure 5). Keys and colleagues examined the
role of Ikaros in the assembly of the human b-globin active
chromatin hub and subsequent globin gene transcription [20].
IkaroswasinvolvedinhumanglobingeneswitchingthroughIkaros-
Eos heterodimers or homodimers [20].
In this study we measured the kinetics of c- and b-globin genes
expression during Epo-induced erythroid maturation of CD34+
HPCs. As shown in Figure 7A, the levels of c-globin mRNA
exhibited marked decreases on the whole and the b-globin mRNA
levels exhibited slight increases in the lenti-Eos-infected CD34+
HPCs after day 7 of erythroid induction culture when the
conversion of c-t ob-globin gene expression occurs. At the same
time, the decline in the ratio of c to [c+b]-globin mRNAs also
appeared to be a little more rapid in the Eos-virus-infected cells
compared with controls (Figure 7B). These results suggest that
enforced Eos expression had a minor effect on c-t ob-globin
switching during erythroid differentiation of HPCs.
In conclusion, the present study suggests that Eos contributes
significantly to the transcriptional regulation of c-globin during
erythroid differentiation of K562 cells and UCB-derived CD34+
HPCs.
Materials and Methods
Cell lines, cell culture, and erythroid induction of K562
cells
Chronic myelogenous leukemia cell line K562 was purchased
from the Cell Center of The Institute of Basic Medical Science,
Chinese Academy of Medical Science. Human embryonic kidney
Figure 6. Enforced expression of Eos inhibited the rise in c-globin gene expression during erythroid differentiation of CD34+ HPCs.
(A) The Eos mRNA level was analyzed by quantitative real-time PCR during Epo-induced erythroid differentiation of UCB-derived CD34+ HPCs. (B–C)
The Eos mRNA level was analyzed by (B) RT-PCR and (C) quantitative real-time PCR in the erythroid induction culture of CD34+ HPCs that were
untreated, infected with lentiviruses carrying the pWPXL vector, or infected with recombinant pWPXL-Eos lentiviruses. (D) Histograms illustrating
globin expression as determined by quantitative real-time PCR in CD34+ HPCs induced into erythroid differentiation for 3, 7, 11, or 15 d. Quantitative
real-time PCR experiments were performed in triplicate and were normalized to b-actin mRNA levels. The relative expression of each mRNA is
depicted as the fold value in mRNA level compared to untreated CD34+ HPCs. Error bars represent one standard deviation. *P,0.05, #P,0.01.
doi:10.1371/journal.pone.0022907.g006
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USA). The mouse erythroleukemia cell line MEL GM979 was a
gift from Dr. Stamatoyannopoulos at University of Washington.
All of the cells were cultured at 37uC and 5% CO2 in RPMI 1640
medium or Dulbecco’s Modified Eagle Medium (GIBCO, NY,
USA), supplemented with 10% fetal bovine serum (GIBCO),
2 mM L-glutamin, 100 U/mL penicillin, and 100 mg/mL strep-
tomycin (Invitrogen, CA, USA). K562 cells were induced into
erythroid differentiation by incubation in medium containing
50 mM hemin (Sigma-Aldrich, Germany). Cells were harvested at
each desired time point (0, 24, 48, and 72 h).
RNA isolation and quantitative real-time PCR analysis
Total RNA was isolated from cells harvested using TRIzol reagent
(Invitrogen) according to the manufacturer’s instructions. RNA was
reverse-transcribed to cDNA using the M-MLV reverse transcriptional
system (Invitrogen). Quantitative real-time PCR were performed using
an iQ5 Real-Time PCR Detection System (Bio-Rad, California, USA)
and SYBR Premix Ex Taq kit (Takara, Dalian, P. R. China). Primers
used in quantitative real-time PCR are listed in Table S2.
Plasmid constructs
The sequences encoding Eos were amplified by PCR from
cDNA derived from K562 cells and cloned into the pcDNA3.1(+)
expression vector (Invitrogen) or the pWPXL retroviral expression
vector (Addgene). The primers Eos-F (59- TGCCTGCGAAAT-
GACGG -39) and Eos-R (59- AGGGCACAAGAGGTATG-
GAGTA -39) were used for PCR amplification.
Promoter region of the c-globin gene (21383 to +49 relative to
the transcription start site) was amplified from human genomic
DNA and cloned into the luciferase reporter vector pGL3-basic
(Promega, Madison, WI, USA). A series of truncated c-globin
promoter regions including 2562 to +49, 2864 to +49, and 2998
to +49, were cloned into the pGL3-basic vector as described
previously [33]. The 3.1-kb micro-LCR (m’LCR) sequence was
amplified from the cosmid construct m’LCRAcybdb [34] by PCR
and was inserted upstream of the c-globin promoter in the pGL3-
basic plasmid. Mutations in the putative Eos binding sequence of
the construct plasmid were introduced using PCR-based site-
directed mutagenesis. The bases TTTC replaced GGGA at LCR
region and GAAA replaced TCCC in the approximately position
2930 of the c-globin gene promoter (Fig. 3A). All plasmids were
prepared using the Plasmid Maxi Kit (Qiagen, CA, USA). All
constructs were sequence-verified.
Northern blot and Western blot
Northern blot analysis of globin mRNAs was performed as
described previously [35]. Briefly, T4 polynucleotide kinase and
c-
32P ATP were used to 59 end-label ssDNA probes (NEB). Probe
sequences are listed in Table S3. Western blot analysis was
performed as described previously [24]. The following primary
antibodies were used: anti-Eos (Santa Cruz Biotechnology, Inc.,
CA, USA), anti-c-globin (Santa Cruz), anti-b-actin (Proteintech,
Group Inc., Chicago, IL), and anti-GAPDH (Proteintech). HRP-
conjugated secondary antibodies were used. Immunoblots were
quantified using AlphaEaseFC software.
Cell transfection and luciferase reporter assay
GM979 cells were stably transformed with m’LCRAcybdb as
described previously [36]. Briefly, 2610
7 cells were cotransfected
with linearized cosmid m’LCRAcybdb and linearized plasmid
pTKneo in HEPES buffered saline by electroporation at 250 V
and 960 mF. Stable GM979 transfectants were selected in medium
containing 130 mg/mL G418 for 2 weeks.
For the dual-luciferase reporter assay, K562 cells were seeded in
24-well plates and cotransfected with plasmid pcDNA3.1-Eos or
with pcDNA3.1 and the luciferase reporter plasmid (pGL3-basic-
based construct and pRL-TK plasmid), respectively, using
Lipofectamine LTX reagent (Invitrogen) according to the
manufacturer’s instructions. The transfection medium was re-
placed with complete medium after 6 h, and cells were cultured
for 48 h. Cells then were lysed using Passive Lysis Buffer
(Promega), and luciferase activities were measured with a Modulus
Microplate Luminometer (Turner Biosystems, CA, USA) using the
Dual-Luciferase Reporter Assay System (Promega) according to
the manufacturer’s instructions.
Chromatin immunoprecipitation-PCR (ChIP-PCR)
Chromatin immunoprecipitation (ChIP) assays were performed
essentially as previously reported [37]. Briefly, uninduced and
hemin-induced K562 cells were harvested and fixed in 1%
formaldehyde (Sigma-Aldrich, Deisenhofen, Germany) at room
temperature for 10 min and quenched for 5 min with glycine.
Cells were lysed and sonicated to obtain chromatin fragments
that were approximately 500–1000 bp in length. ChIP was
performed using the EZ-ChIP Chromatin Immunoprecipita-
tion Kit (Millipore, MA, USA) with minor modifications to
the manufacturer’s instructions. A rabbit polyclonal anti-Eos
Figure 7. The effect of Eos on c-t ob-globin gene switching
during erythroid differentiation. (A) Kinetics of c- and b-globin
gene expression during the erythroid maturation of CD34+ HPCs. ‘‘Eos’’
represents CD34+ HPCs infected with lentiviruses carrying Eos. (B) Ratio
of c to [c+b] mRNA during the erythroid maturation of CD34+ HPCs.
Quantitative real-time PCR assays were performed in triplicate and were
normalized to b-actin mRNA levels. Data were obtained from three
independent experiments, and error bars represent standard deviation.
*P,0.05, #P,0.01.
doi:10.1371/journal.pone.0022907.g007
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antibody, and rabbit IgG (Santa Cruz) was used as the control.
Input and immunoprecipitated DNA were amplified by PCR
using primers listed in Table S1. Quantitative real-time PCR was
performed as described previously [38,39]. Immunoprecipitated
DNA was amplified using SYBR green dye on a Bio-Rad iQ5
Real-Time PCR Detection System, and experimental PCR
products quantified by comparison with the PCR products of a
dilution series of relevant input DNA.
Chromosome conformation capture (3C) assay
The 3C assay was performed as described previously [40,41]
with minor modifications. K562 cells (1610
8) were harvested and
crosslinked with 1% formaldehyde at room temperature for
Figure 8. Overexpression of Eos inhibits erythroid differentiation of K562 cells and CD34+ HPCs. (A) Benzidine staining of K562 cells that
were untransfected, transfected with the control vector (pcDNA3.1), or transfected with the Eos overexpression vector (pcDNA3.1-Eos). The
percentage of benzidine-positive cells in each group was counted following hemin induction periods of 0, 12, 24, 36, or 48 h. Data were obtained
from three independent experiments, and error bars represent standard deviation. *P,0.05. (B) Representative benzidine staining of untransfected
and transfected K562 cells that were hemin-induced for 24 or 48 h. (C–D) Flow cytometric analysis of K562 cells transfected with control or pcDNA-
Eos and treated with (C) anti-transferrin receptor (CD71) or (D) anti-glycophorin A (CD235a) antibodies after 48 h of hemin induction. (E) Quantitative
real-time PCR analysis of CD235a mRNA level during Epo-induced erythroid differentiation of CD34+ HPCs. Error bars represent one standard
deviation. *P,0.05. (F) Flow cytometric analysis of CD235a in K562 cells transfected with lenti-Eos or lenti-control after Epo induction for 15 d.
doi:10.1371/journal.pone.0022907.g008
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0.125 M. After cells were lysed, SDS was added to a final
concentration of 0.1%, and the reaction was incubated at 37uC for
10 min. Triton X-100 then was added to 1%. DNA was digested
with XbaI (NEB) overnight at 37uC. The restriction enzyme was
inactivated with the addition of 1.6% SDS, and the digested DNA
was incubated at 65uC for 20 min. The reaction was diluted to
2.5 ng/mL DNA, and Triton X-100 was added to 1%. DNA was
ligated for 4–5 h at 16uC using T4 ligase (NEB). Cross-links were
reversed by overnight incubation in 5 mg/mL proteinase K at
65uC. DNA was purified by phenol-chloroform extraction and
ethanol precipitation. DNA concentrations were measured using
the NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific
Inc., Bremen, Germany) and were diluted for quantitative real-
time PCR.
To generate the control template with detectable amounts of
randomly ligated DNA fragments, PCR fragments from ligation
products, which spanned each restriction sites, were purified from
the agarose gel to enrich for the ligation products of interest.
Equimolar concentrations of the PCR fragments were mixed,
digested with XbaI, and ligated. The ligated fragments were
purified by phenol extraction and ethanol precipitation and
diluted to an appropriate concentration. Purified fragments
(300 ng) were mixed with the same amount of digested and
randomly ligated genomic DNA. The mixture was used as control
sample for quantitative real-time PCR. The experimental PCR
products were quantified by comparison with the PCR products of
relevant control. The 3C primers used in this study are listed in
Table S4.
Assay of erythroid differentiation: benzidine staining and
flow cytometry
Erythroid differentiation of K562 cells was scored by benzidine
staining as reported previously [42]. Flow cytometry was carried
out according to standard protocols, and samples were analyzed
using a C6 flow cytometer (Accuri Cytometers, MI, USA).
Isolation and erythroid induction of CD34+ HPCs and
recombinant lentivirus generation/infection
Human UCB samples were obtained with informed consent
from normal, full-term deliveries. CD34+ HPCs were purified
from normal UCB using magnetic-activated cell sorting (MACS)
technology according to the manufacturer’s recommendations
(Miltenyi Biotec, Bergisch-Gladbach, Germany). CD34+ HPCs
were cultured in IMDM supplemented with 30% fetal bovine
serum (GIBCO), 1% BSA, 100 mM 2-mercaptoethanol (2-ME)
(Sigma), 2 ng/mL recombinant human interleukin-3 (IL-3),
100 ng/mL recombinant human stem cell factor (SCF) (Pepro-
Tech, London, UK), 2 U/mL recombinant human Epo (R&D
Systems, MN, USA), 60 mg/mL penicillin, and 100 mg/mL
streptomycin. Cells were harvested every 2 d during erythroid
induction.
The expression plasmid pWPXL-Eos was cotransfected with
packaging plasmids into 293TN cells using Lipofectamine with
Plus Reagent (Invitrogen). The packaging kit was purchased from
System Biosciences and operated according to the manufacturer’s
instructions. Recombinant lentivirus particles (i.e., lenti-Eos and
lenti-control) were harvested and added to the medium of CD34+
HPCs in culture. Lentivirus-infected CD34+ HPCs were washed
with PBS and induced to erythroid differentiation with Epo for 2
weeks.
Statistics
Each set of experiments was repeated at least in triplicate, and
standard error values were calculated. Data were analyzed using
Student’s two-tailed t-test, and P-values less than 0.05 were
considered significant.
Supporting Information
Figure S1 Schematic representation of Eos protein
structure. The black ovals represent the zinc finger regions,
and N-terminal DNA-binding zinc fingers can bind to DNA
binding motif sequences (WGGGAAT).
(TIF)
Figure S2 Western blot analysis of Eos expression in
some human cell lines and MELGM979.
(TIF)
Figure S3 Quantitative real-time PCR analysis of mRNA
levels of eight transcription factors in untransfected,
pcDNA3.1-transfected and pc3.1-Eos-transfected K562
cells. (A) Before hemin treatment. (B) After 48 h with hemin
treatment. Each real-time PCR experiment was performed in
triplicate and mRNA level was normalized to b-actin mRNA
expression. The relative expression of each mRNA was shown as
the fold values of mRNA levels in untreated K562 cells.
(TIF)
Table S1 Primers used for ChIP-PCR.
(DOC)
Table S2 Primers used for real-time PCR.
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Table S3 Probes used for Northern blot.
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Table S4 Primers used in the 3C assay.
(DOC)
Acknowledgments
We thank Dr. Stamatoyannopoulos G for the MEL GM979 cell line and
Dr. Shao-Wei Wang from Beijing Hospital for assistance in umbilical cord
blood collection.
Author Contributions
Conceived and designed the experiments: H-CY J-WZ. Performed the
experiments: H-CY H-LZ. Analyzed the data: H-CY J-WZ. Contributed
reagents/materials/analysis tools: J-WZ Z-KW. Wrote the paper: H-CY J-
WZ.
References
1. Mahajan MC, Karmakar S, Weissman SM (2007) Control of beta globin genes.
J Cell Biochem 102: 801–810.
2. Harju S, McQueen KJ, Peterson KR (2002) Chromatin structure and control of
beta-like globin gene switching. Exp Biol Med (Maywood) 227: 683–700.
3. Cunningham JM, Jane SM (1996) Hemoglobin switching and fetal hemoglobin
reactivation. Semin Hematol 33: 9–23.
4. Crossley M, Orkin SH (1993) Regulation of the beta-globin locus. Curr Opin
Genet Dev 3: 232–237.
5. Rodgers GP, Rachmilewitz EA (1995) Novel treatment options in the severe
beta-globin disorders. Br J Haematol 91: 263–268.
6. Song CZ, Gavriilidis G, Asano H, Stamatoyannopoulos G (2005) Functional
study of transcription factor KLF11 by targeted gene inactivation. Blood Cells
Mol Dis 34: 53–59.
7. Asano H, Li XS, Stamatoyannopoulos G (2000) FKLF-2: a novel Kruppel-like
transcriptional factor that activates globin and other erythroid lineage genes.
Blood 95: 3578–3584.
Regulation of Human c-globin Gene by Eos
PLoS ONE | www.plosone.org 11 July 2011 | Volume 6 | Issue 7 | e229078. Zhou W, Clouston DR, Wang X, Cerruti L, Cunningham JM, et al. (2000)
Induction of human fetal globin gene expression by a novel erythroid factor, NF-
E4. Mol Cell Biol 20: 7662–7672.
9. Duan Z, Stamatoyannopoulos G, Li Q (2001) Role of NF-Y in in vivo regulation
of the gamma-globin gene. Mol Cell Biol 21: 3083–3095.
10. Sankaran VG, Menne TF, Xu J, Akie TE, Lettre G, et al. (2008) Human fetal
hemoglobin expression is regulated by the developmental stage-specific repressor
BCL11A. Science 322: 1839–1842.
11. Bottardi S, Ross J, Bourgoin V, Fotouhi-Ardakani N, Affar el B, et al. (2009)
Ikaros and GATA-1 combinatorial effect is required for silencing of human
gamma-globin genes. Mol Cell Biol 29: 1526–1537.
12. Liu LR, Du ZW, Zhao HL, Liu XL, Huang XD, et al. (2005) T to C substitution
at 2175 or 2173 of the gamma-globin promoter affects GATA-1 and Oct-1
binding in vitro differently but can independently reproduce the hereditary
persistence of fetal hemoglobin phenotype in transgenic mice. J Biol Chem 280:
7452–7459.
13. Tanabe O, McPhee D, Kobayashi S, Shen Y, Brandt W, et al. (2007) Embryonic
and fetal beta-globin gene repression by the orphan nuclear receptors, TR2 and
TR4. EMBO J 26: 2295–2306.
14. Aerbajinai W, Zhu J, Kumkhaek C, Chin K, Rodgers GP (2009) SCF induces
gamma-globin gene expression by regulating downstream transcription factor
COUP-TFII. Blood 114: 187–194.
15. Caballero R, Setien F, Lopez-Serra L, Boix-Chornet M, Fraga MF, et al. (2007)
Combinatorial effects of splice variants modulate function of Aiolos. J Cell Sci
120: 2619–2630.
16. Ng SY, Yoshida T, Georgopoulos K (2007) Ikaros and chromatin regulation in
early hematopoiesis. Curr Opin Immunol 19: 116–122.
17. Thompson EC, Cobb BS, Sabbattini P, Meixlsperger S, Parelho V, et al. (2007)
Ikaros DNA-binding proteins as integral components of B cell developmental-
stage-specific regulatory circuits. Immunity 26: 335–344.
18. Sridharan R, Smale ST (2007) Predominant interaction of both Ikaros and
Helios with the NuRD complex in immature thymocytes. J Biol Chem 282:
30227–30238.
19. Pan F, Yu H, Dang EV, Barbi J, Pan X, et al. (2009) Eos mediates Foxp3-
dependent gene silencing in CD4+ regulatory T cells. Science 325: 1142–1146.
20. Keys JR, Tallack MR, Zhan Y, Papathanasiou P, Goodnow CC, et al. (2008) A
mechanism for Ikaros regulation of human globin gene switching. Br J Haematol
141: 398–406.
21. Perdomo J, Crossley M (2002) The Ikaros family protein Eos associates with C-
terminal-binding protein corepressors. Eur J Biochem 269: 5885–5892.
22. Honma Y, Kiyosawa H, Mori T, Oguri A, Nikaido T, et al. (1999) Eos: a novel
member of the Ikaros gene family expressed predominantly in the developing
nervous system. FEBS Lett 447: 76–80.
23. Bao J, Lin H, Ouyang Y, Lei D, Osman A, et al. (2004) Activity-dependent
transcription regulation of PSD-95 by neuregulin-1 and Eos. Nat Neurosci 7:
1250–1258.
24. Hu R, Sharma SM, Bronisz A, Srinivasan R, Sankar U, et al. (2007) Eos, MITF,
and PU.1 recruit corepressors to osteoclast-specific genes in committed myeloid
progenitors. Mol Cell Biol 27: 4018–4027.
25. Zhang JW, Raich N, Enver T, Anagnou NP, Stamatoyannopoulos G (1990)
Butyrate induces expression of transfected human fetal and endogenous mouse
embryonic globin genes in GM 979 erythroleukemia cells. Dev Genet 11:
168–174.
26. Cohen-Barak O, Erickson DT, Badowski MS, Fuchs DA, Klassen CL, et al.
(2007) Stem cell transplantation demonstrates that Sox6 represses epsilon y
globin expression in definitive erythropoiesis of adult mice. Exp Hematol 35:
358–367.
27. Menzel S, Garner C, Gut I, Matsuda F, Yamaguchi M, et al. (2007) A QTL
influencing F cell production maps to a gene encoding a zinc-finger protein on
chromosome 2p15. Nat Genet 39: 1197–1199.
28. Wijgerde M, Grosveld F, Fraser P (1995) Transcription complex stability and
chromatin dynamics in vivo. Nature 377: 209–213.
29. Kleinjan DA, van Heyningen V (2005) Long-range control of gene expression:
emerging mechanisms and disruption in disease. Am J Hum Genet 76: 8–32.
30. Goodwin AJ, McInerney JM, Glander MA, Pomerantz O, Lowrey CH (2001) In
vivo formation of a human beta-globin locus control region core element
requires binding sites for multiple factors including GATA-1, NF-E2, erythroid
Kruppel-like factor, and Sp1. J Biol Chem 276: 26883–26892.
31. Palstra RJ, Tolhuis B, Splinter E, Nijmeijer R, Grosveld F, et al. (2003) The
beta-globin nuclear compartment in development and erythroid differentiation.
Nat Genet 35: 190–194.
32. Patrinos GP, de Krom M, de Boer E, Langeveld A, Imam AM, et al. (2004)
Multiple interactions between regulatory regions are required to stabilize an
active chromatin hub. Genes Dev 18: 1495–1509.
33. Chen Z, Luo HY, Basran RK, Hsu TH, Mang DW, et al. (2008) A T-to-G
transversion at nucleotide 2567 upstream of HBG2 in a GATA-1 binding motif
is associated with elevated hemoglobin F. Mol Cell Biol 28: 4386–4393.
34. Enver T, Raich N, Ebens AJ, Papayannopoulou T, Costantini F, et al. (1990)
Developmental regulation of human fetal-to-adult globin gene switching in
transgenic mice. Nature 344: 309–313.
35. Sawyer ST, Koury MJ, Bondurant MC (1987) Large-scale procurement of
erythropoietin-responsive erythroid cells: assay for biological activity of
erythropoietin. Methods Enzymol 147: 340–352.
36. Junwu Z, Stamatoyannopoulos G (1999) Predominant expression of human
Agamma–in contrast with beta-globin gene in MEL cells transfected with the
construct muLCRAgamma psibeta deltabeta. Chin Med Sci J 14: 31–37.
37. Hodge D, Coghill E, Keys J, Maguire T, Hartmann B, et al. (2006) A global role
for EKLF in definitive and primitive erythropoiesis. Blood 107: 3359–3370.
38. Letting DL, Chen YY, Rakowski C, Reedy S, Blobel GA (2004) Context-
dependentregulationofGATA-1byfriendofGATA-1.ProcNatlAcad SciUSA
101: 476–481.
39. Dore LC, Amigo JD, Dos Santos CO, Zhang Z, Gai X, et al. (2008) A GATA-1-
regulated microRNA locus essential for erythropoiesis. Proc Natl Acad Sci U S A
105: 3333–3338.
40. Tolhuis B, Palstra RJ, Splinter E, Grosveld F, de Laat W (2002) Looping and
interaction between hypersensitive sites in the active beta-globin locus. Mol Cell
10: 1453–1465.
41. Dekker J, Rippe K, Dekker M, Kleckner N (2002) Capturing chromosome
conformation. Science 295: 1306–1311.
42. Cooper MC, Levy J, Cantor LN, Marks PA, Rifkind RA (1974) The effect of
erythropoietin on colonial growth of erythroid precursor cells in vitro. Proc Natl
Acad Sci U S A 71: 1677–1680.
Regulation of Human c-globin Gene by Eos
PLoS ONE | www.plosone.org 12 July 2011 | Volume 6 | Issue 7 | e22907